Innate Pharma S.A.
NASDAQ:IPHABiotechnology
Healthcare
$1.03 +1.91%
+$0.03 today
- Market cap
- $115.05M
- Beta
- 0.89
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.54
52W Low $1.17High $2.63
Volume 0.50M
Average 0.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$50.67M
FY 2025 · Annual
Investing Cash Flow
$7.00M
FY 2025 · Annual
-23.9% YoYFinancing Cash Flow
$5.83M
FY 2025 · Annual
Cash Flow Statement
EUR
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (52.81M) | (58.1M) | (7.57M) | (49.47M) | (49.18M) |
| Depreciation & Amortization | 4.6M | 45.41M | 5.09M | 1.99M | 5.09M |
| Deferred Income Tax | (1.68M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.62M | 4.25M | 4.26M | 3.94M | 4.26M |
| Change in Working Capital | (9.88M) | (12.5M) | (32.09M) | 39.16M | (10.21M) |
| Accounts Receivables | 3.39M | (4.2M) | (13.67M) | 0 | 0 |
| Inventory | (6.27M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (946K) | (7.66M) | (3.89M) | 0 | 0 |
| Other Working Capital | (6.06M) | (636K) | (10.54M) | 39.16M | (10.21M) |
| Other Non-Cash Items | (1.3M) | 1.8M | (2.24M) | (2.53M) | (630.52K) |
| Operating Cash Flow | (58.46M) | (19.15M) | (32.56M) | (6.9M) | (50.67M) |
| Capital Expenditures | (1.33M) | (1.12M) | (2.35M) | (391K) | (134.47K) |
| Acquisitions (Net) | 7K | 0 | 0 | 0 | 4.8K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 3M | 22.77M | 9.59M | 13.51M |
| Other Investing Activities | 406K | (1K) | (1.79M) | 1K | (6.38M) |
| Investing Cash Flow | (917K) | 1.88M | 20.63M | 9.2M | 7M |
| Debt Repayment | 26.63M | (2.03M) | (2.36M) | (8.94M) | (8.56M) |
| Common Stock Issued | 499K | 198K | 395K | 2.93M | 14.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 187K | 198K | 395K | 2.93M | 0 |
| Financing Cash Flow | 26.82M | (1.83M) | (1.97M) | (6.01M) | 5.83M |
| Effect of Forex Changes | (483K) | (428K) | 274K | (505K) | 7.41M |
| Net Change in Cash | (33.04M) | (19.53M) | (13.62M) | (4.21M) | (30.44M) |
| Free Cash Flow | (59.79M) | (20.28M) | (34.91M) | (7.29M) | (50.81M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$49.2M
+ D&A$5.1M
+ Stock-Based Comp$4.3M
+ Deferred Tax$0
- Working Capital-$10.2M
- Other Non-Cash-$630.5K
= Operating Cash Flow-$50.7M
- Capex-$134.5K
= Free Cash Flow-$50.8M
Analysis
FY2025 free cash flow is -$50.8M. FCF conversion is 103.3% of net income. Operating cash flow was -$50.7M, with capex of -$134.5K. The largest bridge item is Working Capital at -$10.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| 6-K | 6-K filing | Nov 5, 2026 | |
| 6-K | 6-K filing | Oct 27, 2026 | |
| 6-K | 6-K filing | Oct 21, 2026 | |
| 6-K | 6-K filing | Oct 20, 2026 |
Does IPHA generate free cash flow?
Innate Pharma S.A. (IPHA) generated -$50.81M of free cash flow in fiscal 2025.
How much operating cash flow does IPHA produce?
Operating cash flow was -$50.67M, before capital expenditures of $134,474.00.
Continue the stock analysis
Jump to another research area for this company.